Artivion/$AORT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Artivion
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
- Ticker
- $AORT
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 1,800
- Headquarters
- Kennesaw, United States
- Website
- artivion.com
Artivion Metrics
BasicAdvanced
$1.1B
-
-$0.07
1.25
-
Price and volume
Market cap
$1.1B
Beta
1.25
52-week high
$48.25
52-week low
$19.16
Average daily volume
592K
Financial strength
Current ratio
3.473
Quick ratio
1.759
Long term debt to equity
0.902
Total debt to equity
0.916
Interest coverage (TTM)
1.38%
Profitability
EBITDA (TTM)
63.715
Gross margin (TTM)
64.37%
Net profit margin (TTM)
-0.67%
Operating margin (TTM)
8.30%
Effective tax rate (TTM)
241.74%
Revenue per employee (TTM)
$260,000
Management effectiveness
Return on assets (TTM)
2.20%
Return on equity (TTM)
-0.73%
Valuation
Price to revenue (TTM)
2.261
Price to book
2.43
Price to tangible book (TTM)
-8.46
Price to free cash flow (TTM)
-62.144
Free cash flow yield (TTM)
-1.61%
Free cash flow per share (TTM)
-0.359
Growth
Revenue change (TTM)
16.40%
Earnings per share change (TTM)
-84.21%
3-year revenue growth (CAGR)
12.77%
10-year revenue growth (CAGR)
10.96%
3-year earnings per share growth (CAGR)
-54.37%
10-year earnings per share growth (CAGR)
-14.29%
What the Analysts think about Artivion
Analyst ratings (Buy, Hold, Sell) for Artivion stock.
Analyst projections of the future price of Artivion stock.
Bulls say / Bears say
Second-quarter revenue rose 11% year on year, or 9% at constant currency, led by On-X growth of 18% and stent-graft growth of 12%. This shows solid momentum in two core product lines. (PR Newswire)
FDA approval of AMDS removes the institutional-review-board hurdle for new US hospital accounts, which could make adoption easier. Artivion estimates the addressable US market at about $150 million a year. (PR Newswire)
The Endospan acquisition gives Artivion the FDA-approved NEXUS system, which offers a minimally invasive option for some aortic-arch patients who have historically had limited alternatives to open surgery. NEXUS also broadens the company’s aortic-arch portfolio, though meaningful US sales are expected to start in 2027. (PR Newswire, PR Newswire)
In May, Artivion cut its 2026 revenue outlook to $480–496 million from $486–504 million and lowered adjusted EBITDA guidance to $100–107 million from $105–110 million. The revisions point to weaker near-term expectations than it had previously set. (PR Newswire)
Despite higher second-quarter sales, Artivion reported a $13.5 million net loss, compared with net income of $1.3 million a year earlier. The gap between revenue growth and reported profit highlights pressure from expenses and acquisition-related costs. (PR Newswire)
The Endospan deal has increased financial strain: Artivion had $363 million of net debt at the end of June, while second-quarter free cash flow was negative $12 million. Higher leverage and cash outflow could limit flexibility as it funds product launches and integration. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2026.
Artivion Financial Performance
Revenues and expenses
Artivion Earnings Performance
Company profitability
Upcoming events
No upcoming events
Artivion News
AllArticlesVideos
Funds containing Artivion
Fund name | Fund size | $AORT weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.06% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.06% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.04% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.